Danaher (DHR) Q2 2026 (USD): EPS 1.94 (exp. 1.84), Revenue 6.3bln (exp. 6.11bln)
Other Metrics (USD):
- Diagnostics Revenue 2.47bln (exp. 2.34bln)
- Life Sciences Revenue 1.88bln (exp. 1.8bln)
- Biotech Revenue 1.92bln (exp. 1.96bln)
COMMENTARY:
- CEO Rainer Blair says Danaher delivered a better-than-expected Q2, with core growth improving versus Q1 and disciplined execution driving high-single-digit adjusted EPS growth, while Life Sciences delivered its strongest quarter in several years and bioprocessing orders grew mid-teens.
GUIDANCE:
- Sees Q3 core revenue growth between 2.0-3.0% Y/Y, and adj. operating profit margin of about 26.5%.
- Raises FY26 guidance; sees FY adj. EPS between USD 8.45-8.60 (exp. 8.45; prev. saw saw 8.35-8.55)
Context
Danaher's Q2 performance exceeded expectations with EPS of 1.94 vs. expected 1.84 and revenue of 6.3 billion vs. 6.11 billion. The CEO's commentary highlights strong growth in Life Sciences and better core performance, which could positively impact sentiment in the biotech and life sciences sectors, while the upgraded FY guidance reinforces confidence in the firm's growth trajectory.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#DANAHER CORP#DHR.US#FOREX#EQUITIES#METALS#EU SESSION#LIFE SCIENCES TOOLS & SERVICES#METALS & MINING#LIFE SCIENCES TOOLS & SERVICES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DHR#DXY#US EQUITIES